Pathophysiology of Diabetes Mellitus

Sonia Smith

Nightingale College

MSN 584-01: Advanced Pathophysiology Across the Lifespan

Dr. Danielle Schaaf

12/15/2024

Pathophysiology of Diabetes Mellitus

Diabetes Mellitus (DM) is a complex metabolic disorder characterized by hyperglycemia, an abnormal condition caused by elevated blood glucose levels (Banday et al., 2020). The occurrence of DM follows a progressive pattern with complex pathogenesis and varied presentation (Banday et al., 2020). DM is, therefore, a serious condition that can cause serious complications and affect a person's quality of life. The pathophysiology of DM, including its diagnosis and prognosis, will determine the treatment option. In health systems, the prevalence of DM continues to surge, posing serious challenges to health efforts to respond to and or contain it. The following analysis examines the pathophysiology of DM by reviewing normal anatomy and physiology, the signs and symptoms of the disease, the functional alterations that contribute to DM, genomic and environmental contributors, and common treatments.

Normal Anatomy

Normal anatomy includes a functioning pancreas and insulin production. For example, the working pancreas plays a vital role in digestion and in regulating blood sugar. In insulin production, the pancreas plays a vital role in glucose homeostasis (Campbell et al., 2020). It contains clusters of cells known as the islets of Langerhans, which house alpha cells that produce glucagon and beta cells that secrete insulin (Campbell et al., 2020). Insulin is needed to regulate blood glucose levels by triggering glucose uptake by cells, resulting in low blood glucose levels.

The normal anatomy also includes transportation and use of glucose. Glucose is a primary source of energy for the body. After ingestion, carbohydrates are broken down into glucose that enters the bloodstream. Insulin enables glucose uptake by binding to insulin receptors on the cell surface, primarily in muscle and adipose tissue (Wang et al., 2020). This

binding triggers a cascade of events leading to the translocation of glucose transporter type 4 (GLUT4) to the cell membrane, allowing glucose to enter the cell (Wang et al., 2020).

Normal Physiology

Normal physiology encompasses insulin and glucose homeostasis and the organization of metabolic pathways. In a healthy person, the pancreas secretes insulin in response to elevated blood glucose levels, i.e., after a meal (Maheshvare et al., 2023). Insulin makes sure that glucose is stored in the liver as glycogen. Insulin also promotes the uptake of glucose by muscle and fat cells. As a result, when blood glucose levels fall, glucagon is released to stimulate glycogen breakdown and glucose release from the liver, thereby helping maintain euglycemia (Adeva-Andany et al., 2019).

The second aspect of normal physiology is the presence of metabolic pathways. Insulin plays a major role in influencing different metabolic pathways. It promotes lipogenesis, the process of converting glucose into fat for storage, and inhibits lipolysis, thereby helping prevent the breakdown of fat (Santoro et al., 2021). Also, insulin stimulates protein synthesis and prevents protein degradation, both of which are necessary for muscle maintenance and growth.

Signs and Symptoms of Diabetes Mellitus

The first, second, and classic most common signs and symptoms of DM are persistent hyperglycemia, characterized by polydipsia, polyphagia, and polyuria. Hyperglycemia occurs when the renal threshold for glucose reabsorption is exceeded, leading to glycosuria and osmotic diuresis, which cause polyuria and dehydration (Dilworth et al., 2021). This then triggers polydipsia. However, even in the presence of hyperglycemia, cells are starved of glucose, leading to polyphagia.

Another set of signs and symptoms is weight loss and fatigue. In type 1 diabetes (T1DM), unintentional weight loss may occur because of the breakdown of muscle and fat for energy in the absence of insulin (Dilworth et al., 2021). Fatigue may result from the inability of cells to use glucose effectively for energy. Other symptoms include blurred vision, frequent infections, slow-healing sores, and tingling or numbness in the hands or feet. Blurred vision can result from osmotic changes in the eye's lens due to fluctuating blood glucose levels. The immune system is compromised in DM, increasing susceptibility to infections. Poor circulation and neuropathy can cause slow wound healing and damage (Dilworth et al., 2021).

Alterations in Function Contributing to Diabetes Mellitus

Furthermore, the following alterations in function contribute to diabetes mellitus. According to Dilworth et al. (2021), hyperglycemia manifests as follows, in T1DM, the destruction of autoimmune beta cells can lead to an absolute deficiency of insulin, and in type 2 diabetes mellitus (T2DM), the alteration is in the form of insulin resistance, especially in the following parts, including the muscles, fat, and liver cells that affect the uptake and utilization of glucose. Initially, the pancreas compensates by increasing insulin secretion. However, beta-cell dysfunction can occur, leading to insulin deficiency.

Further, gluconeogenesis and glycogenolysis are another set of alterations. Increased hepatic gluconeogenesis and glycogenolysis contribute to hyperglycemia in DM. In insulin-resistant states, the liver continues to produce glucose even when blood glucose levels are high, which worsens hyperglycemia (Dilworth et al., 2021). Lipotoxicity and inflammation are other sets of alterations that contribute to diabetes mellitus (Dilworth et al., 2021). Elevated levels of free fatty acids in obesity are a common precursor to T2DM, therefore resulting in insulin resistance. Lipotoxicity affects insulin signaling pathways and triggers chronic inflammation via

adipose tissue macrophage infiltration, which in turn worsens insulin resistance and causes beta-cell dysfunction. Dilworth et al. (2021) furthermore cover that an additional alteration is oxidative stress. This manifests as chronic hyperglycemia, which induces oxidative stress and leads to the generation of reactive oxygen species. This reaction can damage cellular structures; for example, DNA, proteins, and lipids, contributing to the development and progression of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

Genomic and Environmental Contributors to Diabetes Mellitus

The first contributor to genetic predisposition is genetic factors, and they play an important role in the development of DM (Li et al., 2021). In T1DM, certain genetic variants, such as those in the HLA region on chromosome 6, are associated with increased risk (Li et al., 2021). In T2DM, numerous loci have been identified that influence insulin secretion and action. T1DM results from the autoimmune destruction of beta cells, leading to insulin deficiency, whereas T2DM arises from insulin resistance and relative insulin deficiency (Dilworth et al., 2021).

The environmental contributors to DM are as follows. For T1DM, viral infections and early exposure to cow's milk have been shown to increase the risk of developing DM. For T2DM, lifestyle factors, for example, diet, physical inactivity, and obesity, are major contributors. T2DM has been increasing in prevalence globally, and this is mainly associated with the adoption of Western dietary patterns high in fatty and sugary foods and sedentary lifestyles. An additional contributor is epigenetics. According to Li et al. (2021), epigenetic modifications, such as DNA methylation and histone modifications, can influence gene expression without altering the DNA sequence. These changes can be triggered by environmental factors and can contribute to the development of DM.

Common Treatments

The first treatment is insulin therapy. For T1DM, exogenous insulin administration is required for survival. Different insulin preparations, including rapid-acting, short-acting, intermediate-acting, and long-acting, are typically used to mimic physiological insulin secretion and manage blood glucose levels. The second type of treatment is oral hypoglycemic agents. In the management of T2DM, lifestyle modifications are usually required, after which oral hypoglycemic agents are typically added. Metformin is used as a first-line drug to reduce hepatic glucose production and improve insulin sensitivity. Other classes of drugs include sulfonylureas, which stimulate insulin secretion, and SGLT2 inhibitors, which increase renal glucose excretion. Another cornerstone in the treatment of T2DM is the use of glucagon-like peptide (GLP-1) agonists, which can restore insulin secretion at pharmacological levels (Collins & Costello, 2024). Per Collins & Costello (2024), GLP-1 agonists lower serum glucose levels, thereby managing metabolism in T2DM patients.

Per the ADA (2024), a common treatment for DM is lifestyle modification, and diet and exercise are critical components of DM management. A balanced diet low in refined sugars and saturated fats, plus regular physical activity, can improve glycemic control and reduce cardiovascular risk factors (ADA, 2024). Advanced treatments for DM are also emerging; these include continuous glucose monitoring (CGM) systems, insulin pumps, and artificial pancreas systems that automatically regulate blood glucose levels (Elian et al., 2023). Bariatric surgery is also considered for severely obese individuals with T2DM because it can lead to significant weight loss and remission of diabetes; there's also monitoring of blood glucose levels and education (ADA, 2024). Patients can also be educated about the importance of adhering to

medication regimens or recognizing the warning signs of DM, especially hypo- and hyperglycemia, to help them manage their condition effectively.

Conclusion

With T1DM, a person learns early on how to take care of themselves, whether it's monitoring their blood glucose with a meter or using a new insulin pump. T2DM requires important education on diet and exercise, and with good compliance, a person can live a comfortable, full life. Having a disease does not mean it has to be a negative experience; it just means that careful consideration in everyday life is fundamental. T1DM and T2DM both require a lifestyle change; proper diet and exercise will help a patient with DM not only feel better but will help them have fewer complications with their disease.

DM is impactful genetically, environmentally, and especially impactful to a person's lifestyle. Advanced Practice Nurses need to understand DM pathophysiology, for it is crucial for developing effective treatments and management strategies for their patients. T1DM requires lifelong insulin therapy, and T2DM can be managed with lifestyle modifications and pharmacotherapy. Advances in research continue to provide information into the mechanisms underlying DM, offering hope for improved therapies and, ultimately, a cure.

References

Adeva-Andany, M. M., Funcasta-Calderón, R., Fernández-Fernández, C., Castro-Quintela, E., & Carneiro-Freire, N. (2019). Metabolic effects of glucagon in humans. *Journal of Clinical & Translational Endocrinology*, *15*, 45–53. https://doi.org/10.1016/j.jcte.2018.12.005

ADA. (2024). *Lifestyle Change Programs* https://diabetes.org/tools-resources/diabetes-education/lifestyle-change-programs

Banday, M., Sameer, A., & Nissar, S. (2020). Pathophysiology of diabetes: An overview. *Avicenna Journal of Medicine*, *10*(4), 174–188. https://doi.org/10.4103/ajm.ajm_53_20

Campbell, S. A., Golec, D. P., Hubert, M., Johnson, J., Salamon, N., Barr, A., MacDonald, P. E., Koenraad Philippaert, & Light, P. E. (2020). Human islets contain a subpopulation of glucagon-like peptide-1 secreting α cells that is increased in type 2 diabetes. *Molecular Metabolism*, *39*, 101014–101014. https://doi.org/10.1016/j.molmet.2020.101014

Collins, L., & Costello, R. A. (2024, February 29). *Glucagon-like peptide-1 receptor agonists*. https://www.ncbi.nlm.nih.gov/books/NBK551568/

Dilworth, L., Facey, A., & Omoruyi, F. (2021). Diabetes Mellitus and its metabolic complications: The role of adipose tissues. *International Journal of Molecular Sciences*, *22*(14), 7644. https://doi.org/10.3390/ijms22147644

Elian, V., Popovici, V., Emma-Adriana Ozon, Adina Magdalena Musuc, Ancuța Cătălina Fița, Rusu, E., Radulian, G., & Dumitru Lupuliasa. (2023). Current technologies for

managing Type 1 Diabetes Mellitus and their impact on quality of life—a narrative review. *Life*, *13*(8), 1663–1663. https://doi.org/10.3390/life13081663

Li, D., Yang, Y., Li, Y., Zhu, X., & Li, Z. (2021). Epigenetic regulation of gene expression in response to environmental exposures: From bench to model. *Science of the Total Environment*, *776*, 145998. https://doi.org/10.1016/j.scitotenv.2021.145998

Maheshvare, Raha, S., Matthias König, & Pal, D. (2023). A pathway model of glucose stimulated insulin secretion in the pancreatic β-cell. *Frontiers in Endocrinology*, *14*. https://doi.org/10.3389/fendo.2023.1185656

Santoro, A., McGraw, T. E., & Kahn, B. B. (2021). Insulin action in adipocytes, adipose remodeling, and systemic effects. *Cell Metabolism*, *33*(4), 748–757. https://doi.org/10.1016/j.cmet.2021.03.019

Wang, T., Wang, J., Hu, X., Huang, X.-J., & Chen, G.-X. (2020). Current understanding of glucose transporter 4 expression and functional mechanisms. *World Journal of Biological Chemistry*, *11*(3), 76–98. https://doi.org/10.4331/wjbc.v11.i3.76